-
1Academic Journal
Authors: R. N. Trushkin, E. A. Baryakh, P. E. Medvedev, Yu. A. Lagoyskaya, E. A. Semenova, D. V. Fettser, A. A. Chumikov, T. K. Isaev, Р. Н. Трушкин, Е. А. Барях, П. Е. Медведев, Ю. А. Лагойская, Е. А. Семенова, Д. В. Фетцер, А. А. Чумиков, Т. К. Исаев
Source: Cancer Urology; Том 20, № 3 (2024); 130-135 ; Онкоурология; Том 20, № 3 (2024); 130-135 ; 1996-1812 ; 1726-9776
Subject Terms: простатический специфический антиген, non-Hodgkin lymphoma, prostate, rare prostate tumors, prostate specific antigen, мантийноклеточная лимфома, неходжкинская лимфома, предстательная железа, редкая опухоль предстательной железы
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1796/1562; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1796/1489; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1796/1490; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1796/1491; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1796/1492; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1796/1493; Teras L.R., DeSantis C.E., Cerhan J.R. et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Canser J Clin 2016;66(6):443–59. DOI:10.3322/caac.21357; Armitage J.O., Longo D.L. Mantle cell lymphoma. N Engl J Med 2022;386(26):2495–506. DOI:10.1056/NEJMra2202672; Campo E., Jaffe E.S., Cook J.R. et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022;140(11):1229–53. DOI:10.1182/blood.2022015851; Alaggio R., Amador C., Anagnostopoulos I. et al. The 5th edition of the World Health Organisation Classification of hematolymphoid tumors: Lymphoid Neoplasms. Leukemia 2022;36(7):1720–48. DOI:10.1038/s41375-022-01620-2; Olweny C.L. Cotswolds modification of the Ann Arbor staging system for Hodgkin’s disease. J Clin Oncol 1990;8(9):1598.; Hoster E., Dreyling M., Klapper W. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111(2):558–6. DOI:10.1182/blood-2007-06-095331; Воробьев В.И., Тумян Г.С. Лимфома из клеток мантии. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. 2020.; Doshi K., Chandran A., Li Y. et al. Mantle zone lymphoma with prostate gland enlargement: a case report. Cureus 2022;14(11):e32045. DOI:10.7759/cureus.32045; Dreyling M.M., Doorduijn J.K., Gine E. et al. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL Network. Blood 2022;140(Suppl 1):1–3.; National Comprehensive Cancer Network. Available at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf; Belkacemi Y., Sio T.T., Colson-Durand L. et al. Primary extranodal lymphoma of the glands. Literature review and options for best practice in 2019. Crit Rev Oncol Hematol 2019;135:8–19. DOI:10.1016/j.critrevonc.2019.01.005; Milburn P.A., Cable C.T., Trevathan S., El Tayeb M.M. Mantle cell lymphoma of the prostate gland treated with holmium laser enucleation. Proc (Bayl Univ Med Cent) 2017;30(3):338–9. DOI:10.1080/08998280.2017.11929640; Karademir B., Kısa E., Özbilen M.H. et al. Unexpected hematologic malignancies after prostatectomy: case report and literature review. Urologia 2021;88(4):382–5. DOI:10.1177/0391560321993596; Kumar P., Rahman K., Hussein N. et al. Primary prostatic nonHodgkin’s lymphoma presenting with features of prostatism. J Cancer Res Ther 2019;15:178–9. DOI:10.4103/jcrt.JCRT_886_16; https://oncourology.abvpress.ru/oncur/article/view/1796
-
2Academic Journal
Authors: Luchytskyy, V.Ye., Tronko, M.D., Luchytskyy, Ye.V.
Source: Mìžnarodnij Endokrinologìčnij Žurnal, Vol 15, Iss 2, Pp 99-105 (2019)
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY; Том 15, № 2 (2019); 99-105
Международный эндокринологический журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 15, № 2 (2019); 99-105
Міжнародний ендокринологічний журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 15, № 2 (2019); 99-105Subject Terms: type 2 diabetes mellitus, hematocrit, тестостерон, чоловіки, цукровий діабет 2-го типу, простатичний специфічний антиген, гематокрит, передміхурова залоза, testosterone, mеn, prostate-specific antigen, prostate gland, RC648-665, мужчины, сахарный диабет 2-го типа, простатический специфический антиген, предстательная железа, Diseases of the endocrine glands. Clinical endocrinology, 3. Good health, 03 medical and health sciences, 0302 clinical medicine
File Description: application/pdf
-
3Academic Journal
Authors: S.D. Efremova, V.M. Nikolaev, S.I. Sofronova, E.K. Rumyantsev, E.D. Okhlopkova, N.K. Chirikova, S.A. Fedorova
Source: Yakut Medical Journal. :13-16
Subject Terms: 2. Zero hunger, альфа-фетопротеин (АФП), простатический специфический антиген (ПСА), онкомаркеры, онкомаркер яичников (СА125), раково-эмбриональный антиген (РЭА), курение, 3. Good health
-
4Academic Journal
Authors: Z. M. Akhokhov, R. S. Ismailov, M. I. Kogan, З. М. Ахохов, Р. С. Исмаилов, М. И. Коган
Source: Urology Herald; Том 11, № 3 (2023); 98-107 ; Вестник урологии; Том 11, № 3 (2023); 98-107 ; 2308-6424 ; 10.21886/2308-6424-2023-11-3
Subject Terms: обзор литературы, benign prostatic hyperplasia, prostate cancer, lower urinary tract symptoms, prostate specific antigen, molecular biological markers, ribonucleic acid, review, доброкачественная гиперплазия предстательной железы, рак предстательной железы, симптомы нижних мочевых путей, простатический специфический антиген, молекулярно-биологические маркёры, рибонуклеиновая кислота
File Description: application/pdf
Relation: https://www.urovest.ru/jour/article/view/760/498; Li J, Shi Q, Bai Y, Pu C, Tang Y, Yuan H, Wu Y, Wei Q, Han P. Efficacy and safety of muscarinic antagonists as add-on therapy for male lower urinary tract symptoms. Sci Rep. 2014;4:3948. DOI:10.1038/srep03948; Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016;43(3):289-97. DOI:10.1016/j.ucl.2016.04.001; Аполихин О.И., Сивков А.В., Комарова В.А., Никушина А.А. Болезни предстательной железы в Российской Федерации: статистические данные 2008-2017 гг. Экспериментальная и клиническая урология. 2019;(2):4-13. DOI:10.29188/2222-8543-2019-11-2-4-12.; Zhu C, Wang DQ, Zi H, Huang Q, Gu JM, Li LY, Guo XP, Li F, Fang C, Li XD, Zeng XT. Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019. Mil Med Res. 2021;8(1):64. DOI:10.1186/s40779-021-00359-8; Platz EA, Joshu CE, Mondul AM, Peskoe SB, Willett WC, Giovannucci E. Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. J Urol. 2012;188(2):496-501. DOI:10.1016/j.juro.2012.03.125; Garg A, Bansal S, Saha S, Kumar A. Study of correlation of urodynamic profile with symptom scoring and ultrasonographic parameters in patients with benign prostatic hyperplasia. J Family Med Prim Care. 2020;9(1):215-220. DOI:10.4103/jfmpc.jfmpc_698_19; Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011;59(5):671-81. DOI:10.1016/j.eururo.2011.01.044; Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-54. DOI:10.1016/0092-8674(93)90529-y; McGuire A, Brown JA, Kerin MJ. Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev. 2015;34(1):145-55. DOI:10.1007/s10555-015-9551-7; Гареев И.Ф., Бейлерли О.А. Циркулирующие микроРНК как биомаркеры: какие перспективы? Профилактическая медицина. 2018;21(6):142‑150. DOI:10.17116/profmed201821061142; Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary microRNAs by the Microprocessor complex. Nature. 2004;432(7014):231-5. DOI:10.1038/nature03049; Broughton JP, Lovci MT, Huang JL, Yeo GW, Pasquinelli AE. Pairing beyond the Seed Supports MicroRNA Targeting Specificity. Mol Cell. 2016;64(2):320-333. DOI:10.1016/j.molcel.2016.09.004; de Rie D, Abugessaisa I, Alam T, Arner E, Arner P, Ashoor H, Åström G, Babina M, Bertin N, Burroughs AM, Carlisle AJ, Daub CO, Detmar M, Deviatiiarov R, Fort A, Gebhard C, Goldowitz D, Guhl S, Ha TJ, Harshbarger J, Hasegawa A, Hashimoto K, Herlyn M, Heutink P, Hitchens KJ, Hon CC, Huang E, Ishizu Y, Kai C, Kasukawa T, Klinken P, Lassmann T, Lecellier CH, Lee W, Lizio M, Makeev V, Mathelier A, Medvedeva YA, Mejhert N, Mungall CJ, Noma S, Ohshima M, Okada-Hatakeyama M, Persson H, Rizzu P, Roudnicky F, Sætrom P, Sato H, Severin J, Shin JW, Swoboda RK, Tarui H, Toyoda H, Vitting-Seerup K, Winteringham L, Yamaguchi Y, Yasuzawa K, Yoneda M, Yumoto N, Zabierowski S, Zhang PG, Wells CA, Summers KM, Kawaji H, Sandelin A, Rehli M; FANTOM Consortium; Hayashizaki Y, Carninci P, Forrest ARR, de Hoon MJL. An integrated expression atlas of miRNAs and their promoters in human and mouse. Nat Biotechnol. 2017;35(9):872-878. DOI:10.1038/nbt.3947; Tanzer A, Stadler PF. Molecular evolution of a microRNA cluster. J Mol Biol. 2004;339(2):327-35. DOI:10.1016/j.jmb.2004.03.065; Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet. 2004;5(5):396-400. DOI:10.1038/nrg1328; Fabris L, Ceder Y, Chinnaiyan AM, Jenster GW, Sorensen KD, Tomlins S, Visakorpi T, Calin GA. The Potential of MicroRNAs as Prostate Cancer Biomarkers. Eur Urol. 2016;70(2):312-22. DOI:10.1016/j.eururo.2015.12.054; Greco F, Inferrera A, La Rocca R, Navarra M, Casciaro M, Grosso G, Gangemi S, Ficarra V, Mirone V. The Potential Role of MicroRNAs as Biomarkers in Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. Eur Urol Focus. 2019;5(3):497-507. DOI:10.1016/j.euf.2018.01.008; Sharova E, Grassi A, Marcer A, Ruggero K, Pinto F, Bassi P, Zanovello P, Zattoni F, D'Agostino DM, Iafrate M, Ciminale V. A circulating miRNA assay as a first-line test for prostate cancer screening. Br J Cancer. 2016;114(12):1362-6. DOI:10.1038/bjc.2016.151; Paziewska A, Mikula M, Dabrowska M, Kulecka M, Goryca K, Antoniewicz A, Dobruch J, Borowka A, Rutkowski P, Ostrowski J. Candidate diagnostic miRNAs that can detect cancer in prostate biopsy. Prostate. 2018;78(3):178-185. DOI:10.1002/pros.23427; Al-Kafaji G, Said HM, Alam MA, Al Naieb ZT. Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer-risk stratification. Oncol Lett. 2018;16(1):1357-1365. DOI:10.3892/ol.2018.8778; Cochetti G, Poli G, Guelfi G, Boni A, Egidi MG, Mearini E. Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role. Onco Targets Ther. 2016;9:7545-7553. DOI:10.2147/OTT.S119027; Dülgeroğlu Y, Eroğlu O. Serum Levels of miR-223-3p and miR-223-5p in Prostate Diseases. Microrna. 2020;9(4):303-309. DOI:10.2174/2211536609666201106090458; Knyazev EN, Fomicheva KA, Mikhailenko DS, Nyushko KM, Samatov TR, Alekseev BY, Shkurnikov MY. Plasma Levels of hsa-miR-619-5p and hsa-miR-1184 Differ in Prostatic Benign Hyperplasia and Cancer. Bull Exp Biol Med. 2016;161(1):108-11. DOI:10.1007/s10517-016-3357-7; Jin W, Fei X, Wang X, Chen F, Song Y. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia. J Immunol Res. 2020;2020:5873056. DOI:10.1155/2020/5873056; Wang H, Yang L, Mi Y, Wang Y, Ma C, Zhao J, Liu P, Gao Y, Li P. Diagnostic Value of Prostate-Specific Antigen Combined with Plasma miRNA-149 Expression in Patients with Prostate Cancer Based on Experimental Data and Bioinformatics. Contrast Media Mol Imaging. 2022;2022:6094409. DOI:10.1155/2022/6094409; Coradduzza D, Solinas T, Balzano F, Culeddu N, Rossi N, Cruciani S, Azara E, Maioli M, Zinellu A, De Miglio MR, Madonia M, Falchi M, Carru C. miRNAs as Molecular Biomarkers for Prostate Cancer. J Mol Diagn. 2022;24(11):1171-1180. DOI:10.1016/j.jmoldx.2022.05.005; Abramovic I, Vrhovec B, Skara L, Vrtaric A, Nikolac Gabaj N, Kulis T, Stimac G, Ljiljak D, Ruzic B, Kastelan Z, Kruslin B, Bulic-Jakus F, Ulamec M, Katusic-Bojanac A, Sincic N. MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia. Cancers (Basel). 2021;13(9):2068. DOI:10.3390/cancers13092068; Yun SJ, Jeong P, Kang HW, Kim YH, Kim EA, Yan C, Choi YK, Kim D, Kim JM, Kim SK, Kim SY, Kim ST, Kim WT, Lee OJ, Koh GY, Moon SK, Kim IY, Kim J, Choi YH, Kim WJ. Urinary MicroRNAs of Prostate Cancer: Virus-Encoded hsv1-miRH18 and hsv2-miR-H9-5p Could Be Valuable Diagnostic Markers. Int Neurourol J. 2015;19(2):74-84. DOI:10.5213/inj.2015.19.2.74; Kang HW, Byun YJ, Moon SM, Kim K, Piao XM, Zheng CM, Moon SK, Choi YH, Kim WT, Kim YJ, Lee SC, Yun SJ, Kim WJ. Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone. Investig Clin Urol. 2022;63(2):238-244. DOI:10.4111/icu.20210493; Byun YJ, Piao XM, Jeong P, Kang HW, Seo SP, Moon SK, Lee JY, Choi YH, Lee HY, Kim WT, Lee SC, Cha EJ, Yun SJ, Kim WJ. Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer. Investig Clin Urol. 2021;62(3):340-348. DOI:10.4111/icu.20200488; Guzel E, Karatas OF, Semercioz A, Ekici S, Aykan S, Yentur S, Creighton CJ, Ittmann M, Ozen M. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer. Int J Cancer. 2015;136(4):875-9. DOI:10.1002/ijc.29054; Bernardes JGB, Fernandes MR, Rodrigues JCG, Vinagre LWMS, Pastana LF, Dobbin EAF, Medeiros JAG, Dias Junior LB, Bernardes GM, Bernardes IMM, Santos NPCD, Demachki S, Burbano RMR. Association of Androgenic Regulation and MicroRNAs in Acinar Adenocarcinoma of Prostate. Genes (Basel). 2022;13(4):622. DOI:10.3390/genes13040622; Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011;60(4):809-25. DOI:10.1016/j.eururo.2011.06.037; Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU Int. 2015;115(4):508-19. DOI:10.1111/bju.12745; Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42(8):1273-81. DOI:10.1016/j.biocel.2009.12.014; Kim WT, Kim WJ. MicroRNAs in prostate cancer. Prostate Int. 2013;1(1):3-9. DOI:10.12954/PI.12011; Плевако Д.С., Князева М.С., Сидина Е.И., Беркут М.В., Рева С.А., Толмачев С.С., Артемьева А.С., Носов А.К., Малек А.В. Влияние таксанов на экспрессию miR-106 и miR-200с клетками рака предстательной железы in vivo и in vitro. Вестник урологии. 2022;10(4):98-108. DOI:10.21886/2308-6424-2022-10-4-98-108; Старцев В.Ю., Шпоть Е.В., Караев Д.К., Кривоносов Д.И. Выявление рака предстательной железы у мужчин молодого и среднего возрастов. Вестник урологии. 2022;10(1):110-120. DOI:10.21886/2308-6424-2022-10-1-110-120; Song C, Chen H, Wang T, Zhang W, Ru G, Lang J. Expression profile analysis of microRNAs in prostate cancer by next-generation sequencing. Prostate. 2015;75(5):500-16. DOI:10.1002/pros.22936; Fang YX, Gao WQ. Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene. 2014;33(2):135-47. DOI:10.1038/onc.2013.54; Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, Thorsen K, Ostenfeld MS, Wild PJ, Arsov C, Goering W, Visakorpi T, Egevad L, Lindberg J, Grönberg H, Høyer S, Borre M, Ørntoft TF, Sørensen KD. Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin Cancer Res. 2014;20(8):2169-81. DOI:10.1158/1078-0432.CCR-13-2642; Alcaraz A, Hammerer P, Tubaro A, Schröder FH, Castro R. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol. 2009;55(4):864-73. DOI:10.1016/j.eururo.2008.11.011; https://www.urovest.ru/jour/article/view/760
-
5Academic Journal
Authors: A. D. Kaprin, S. A. Ivanov, O. B. Karyakin, A. A. Obuhov, V. A. Biryukov, N. B. Borysheva, D. B. Sanin, O. G. Lepilina, A. L. Smolkin, A. V. Dem’yanovich, N. G. Minaeva, N. V. Mikhaylovskiy, А. Д. Каприн, С. А. Иванов, О. Б. Карякин, А. А. Обухов, В. А. Бирюков, Н. Б. Борышева, Д. Б. Санин, О. Г. Лепилина, А. Л. Смолкин, А. В. Демьянович, Н. Г. Минаева, Н. В. Михайловский
Source: Cancer Urology; Том 16, № 4 (2020); 112-119 ; Онкоурология; Том 16, № 4 (2020); 112-119 ; 1996-1812 ; 1726-9776
Subject Terms: внутритканевая лучевая терапия, recurrent prostate cancer, prostate-specific antigen, salvage brachytherapy, high-dose-rate brachytherapy, interstitial radiotherapy, рецидив рака предстательной железы, простатический специфический антиген, сальважная брахитерапия, спасительная брахитерапия, высокомощностная брахитерапия
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1316/1221; Guidlines of Europen Assosiation of Urology, 2020, www.uroweb.org.; Состояние онкологической помощи населению России в 2018 году. Под редакцией А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Москва; 2019.; NCCN Prostate cancer Brachytherapy. NCCN Guidelines for patients Prostate cancer, 2019.; Брахитерапия. Под общей редакцией акад. РАН А. Д. Каприна, чл.-корр. РАН Ю.С. Мардынского. МРНЦ им. А. Ф. Цыба - филиал ФГБУ "НМИЦ радиологии»" Минздрава России. Обнинск, 2017. ISBN 978-5-901968-28-4; Tisseverasinghe SA, Crook JM. The role of salvage brachytherapy for local relapse after external beam radiotherapy for prostate cancer. Transl Androl Urol 2018;7(3):414-435. DOI:10.21037/tau.2018.05.09.; Солодкий В.А., Павлов А.Ю., Цыбульский А.Д. Спасительная брахитерапия высокой мощности дозы при местном рецидиве рака предстательной железы после радикальных радиотерапевтических методов лечения. Онкоурология, Т. 12, № 4 (2016), с. 81-6,. DOI:10.17650/1726-9776-2016-12-4-81-86.; Терапевтическая радиология: национальное руководство / под ред. А. Д. Каприна, Ю. С. Мардынского. - М.: ГЭОТАР-Медиа, 2018. - 704 с. - ISBN 978-5-9704-4658-4.; Olarte A., Cambeiro M., Moreno-Jiménez M. et al. Dose escalation with external beamradiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes. Brachytherapy 2016;15(2):127–35. DOI:10.1016/j.brachy.2015.12.008. PMID: 26832677.; Matei DV, Ferro M, Jereczek-Fossa BA, et al. Salvage radical prostatectomy after external beam radiation therapy: a systematic review of current approaches. Urol Int 2015;94(4):373–82. DOI:10.1159/000371893.PMID: 25765848.; Grado GL, Collins JM, Kriegshauser JS, et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53(1): 2– 10. PMID: 9886580.; Каприн А.Д., Галкин В.Н., Иванов С.А. Роль брахитерапии в лечении локализованных форм рака предстательной железы. Biomedical Photonics, 2015. Т.4, №4. С. 21-26.; https://oncourology.abvpress.ru/oncur/article/view/1316
-
6Academic Journal
Authors: A. A. Musaelyan, V. D. Nazarov, S. V. Lapin, A. G. Boriskin, S. A. Reva, D. G. Lebedev, V. D. Yakovlev, D. A. Viktorov, A. N. Toropovskiy, V. L. Emanuel, S. Kh. Al-Shukri, S. B. Petrov, А. А. Мусаелян, В. Д. Назаров, С. В. Лапин, А. Г. Борискин, С. А. Рева, Д. Г. Лебедев, В. Д. Яковлев, Д. А. Викторов, А. Н. Тороповский, В. Л. Эмануэль, С. Х. Аль-Шукри, С. Б. Петров
Source: Cancer Urology; Том 16, № 2 (2020); 65-73 ; Онкоурология; Том 16, № 2 (2020); 65-73 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2020-16-2
Subject Terms: индекс здоровья предстательной железы, prostate cancer early detection, genetic marker of prostate cancer, PCA3, TMPRSS2:ERG, prostatic specific antigen, PSA derivatives, prostate health index, диагностика рака предстательной железы, генетический маркер рака предстательной железы, TMPRSS2ERG, простатический специфический антиген, дериваты ПСА
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1013/1175; Bray F., Ferlay J., Soerjomataram I. et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2018. DOI:10.3322/caac.21492.; Mottet N., Bellmunt J., Bolla M. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2017;71(4):618—29. DOI:10.1016/j.eururo.2016.08.003.; Leyten G.H., Hessels D., Jannink S.A. et al. Prospective multicentre evaluation of PCA3 and TMPRSS2:ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014;65(3):534—42. DOI:10.1016/j.eururo.2012.11.014.; Hendriks R.J., Van Oort I.M., Schalken J.A. Blood-based and urinary prostate cancer biomarkers: A review and comparison of novel biomarkers for detection and treatment decisions. Prostate Cancer Prostatic Dis 2017;20(1):12—9. DOI:10.1038/pcan.2016.59.; Scattoni V., Lazzeri M., Lughezzani G. et al. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J Urol 2013;190(2):496—501. DOI:10.1016/j.juro.2013.02.3184.; Yang Z., Yu L., Wang Z. PCA3 and TMPRSS2:ERG gene fusions as diagnostic biomarkers for prostate cancer. Chinese J Cancer Res 2016;28(1):65—71. DOI:10.3978/j.issn.1000-9604.2016.01.05.; Zhou F., Gao S., Han D. et al. TMPRSS2:ERG activates NO-cGMP signaling in prostate cancer cells. Oncogene 2019;38(22):4397-411. DOI:10.1038/s41388-019-0730-9.; Martignano F., Rossi L., Maugeri A. et al. Urinary RNA-based biomarkers for prostate cancer detection. Clin Chim Acta 2017;473:96-105. DOI:10.1016/j.cca.2017.08.009.; Catalona W.J., Partin A.W., Sanda M.G. et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011;185(5):1650-5. DOI:10.1016/j.juro.2010.12.032.; Koo K.M., Mainwaring P.N., Tomlins S.A., Trau M. Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management. Nat Rev Urol 2019;16(5):302-17. DOI:10.1038/s41585-019-0178-2.; Carroll P.H., Mohler J.L. NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection. J Natl Compr Cancer Netw J Natl Compr Canc Netw 2018;16:620-3. DOI:10.6004/jnccn.2018.0036.; Cui Y., Cao W., Li Q. et al. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis. Sci Rep 2016;6:25776. DOI:10.1038/srep25776.; Тороповский А.Н., Никитин А.Г., Гордиев М.Г и др. Результаты испытания набора реагентов для выявления мРНК гена РСА3 и определения уровня его экспрессии методом двустадийной ОТ-ПЦР-РВ (Проста-Тест) для диагностики рака предстательной железы in vitro в клинической практике. Вестник медицинского института «РЕАВИЗ» 2018;1:126-36.; Павлов К.А., Шкопоров А.Н., Хохлова Е.В. и др. Разработка диагностической тест-системы для ранней неинвазивной диагностики рака простаты, основанной на количественной детекции мРНК гена PCA3 в осадке мочи методом ОТ-ПЦР в режиме реального времени. Вестник РАМН 2013;(5):45—51.; Merola R., Tomao L., Antenucci A. et al. PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: A National Cancer Institute experience. J Exp Clin Cancer Res 2015;34(1):15. DOI:10.1186/s13046-015-0127-8.; Аполихин О.И., Сивков А.В., Ефремов ГД. и др. РСА3 и TMPRSS2:ERG в диагностике рака предстательной железы: первый опыт применения комбинации маркеров в России. Экспериментальная клиническая урология 2015;(2):30—5.; Park K., Dalton J.T., Narayanan R. et al. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol 2014;32(3):206-11. DOI:10.1200/JCO.2013.49.8386.; Wang Z., Wang Y., Zhang J. et al. Significance of the TMPRSS2:ERG gene fusion in prostate cancer. Mol Med Rep 2017;16(4):5450-8. DOI:10.3892/mmr.2017.7281.; Fujita K., Nonomura N. Urinary biomarkers of prostate cancer. Int J Urol 2018;25(9):770-9. DOI:10.1111/iju.13734.; Sanda M.G., Feng Z., Howard D.H. et al. Association between combined TMPRSS2:ERG and PCA3 RNA urinary testing and detection of aggressive prostate cancer. JAMA Oncol 2017;3(8):1085-93. DOI:10.1001/jamaoncol.2017.0177.; Van Hoof A., Bunn W., Klein A., Albala D. Role of molecular diagnostics in prostate cancer. Surg Proced Core Urol Trainees 2018:151-77. DOI:10.1007/978-3-319-57442-4_17.; Perdona S., Bruzzese D., Ferro M. et al. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate 2013;73(3):227-35. DOI:10.1002/pros.22561.; De la Calle C., Patil D., Wei J.T. et al. Multicenter evaluation of the prostate health index to detect aggressive prostate cancer in biopsy Naive men. J Urol 2015;194(1):65-72. DOI:10.1016/j.juro.2015.01.091.; https://oncourology.abvpress.ru/oncur/article/view/1013
-
7Academic Journal
Source: Естественные и технические науки.
Subject Terms: простатический специфический антиген, альфа-фетопротеин, CA125, alpha-fetoprotein, quality of life, tumor markers, онкомаркеры, prostate specific antigen, качество жизни, 3. Good health
-
8Academic Journal
Authors: Spirina L.V., Gorbunov A.K., Kondakova I.V., Usynin E.A., Slonimskaya E.M.
Contributors: Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, НИИ онкологии ФГБНУ «Томский национальный исследовательский медицинский центр РАН»
Source: Advances in Molecular Oncology; Vol 6, No 1 (2019); 44-48 ; Успехи молекулярной онкологии; Vol 6, No 1 (2019); 44-48 ; 2413-3787 ; 2313-805X
Subject Terms: prostate cancer, AR, ER, testosterone, prostate specific antigen, androgen-deprivation therapy, рак предстательной железы, тестостерон, простатический специфический антиген, андрогендепривационная терапия
File Description: application/pdf
Relation: https://umo.abvpress.ru/jour/article/view/205/173; https://umo.abvpress.ru/jour/article/view/205
-
9Academic Journal
Authors: Р. V. Bulychkin, S. I. Tkachev, V. B. Matveev, A. V. Nazarenko, П. В. Булычкин, С. И. Ткачев, B. Б. Матвеев, А. В. Назаренко
Source: Cancer Urology; Том 15, № 2 (2019); 66-72 ; Онкоурология; Том 15, № 2 (2019); 66-72 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2019-15-2
Subject Terms: период удвоения простатического специфического антигенa, recurrence of prostate cancer, radical prostatectomy, salvage radiotherapy, prostate specific antigen, prostate specific antigen doubling time, рецидив рака предстательной железы, радикальная простатэктомия, спасительная лучевая терапия, простатический специфический антиген
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/902/850; Cookson M.S., Aus G., Burnett A.L. et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer. the American Urological Association Prostate Guidelines for Localized Prostate Cancer. Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urology 2007;177(2):540–5. DOI:10.1016/j.juro.2006.10.097. PMID: 17222629.; Boccon-Gibod L., Djavan W.B., Hammerer P. et al. Management of prostatespecific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 2004;58(4):382–90. PMID: 15161124.; Stephenson A.J., Scardino P.T., Kattan M.W. et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25(15):2035–41. DOI:10.1200/JCO.2006.08.9607. PMID: 17513807.; Siegmann A., Bottke D., Faehndrich J. et al. Salvage radiotherapy after prostatectomy – what is the best time to treat? Radiother Oncol 2012;103(2):239–43. DOI:10.1016/j.radonc.2011.10.024. PMID: 22119375.; Shelan M., Abo-Madyan Y., Welzel G. et al. Dose-escalated salvage radiotherapy after radical prostatectomy in high risk prostate cancer patients without hormone therapy: outcome, prognostic factors and late toxicity. Radiat Oncol 2013;8:276. DOI:10.1186/1748-717X-8-276. PMID: 24279376.; Kwon O., Kim K.B., Lee Y.I. et al. Salvage radiotherapy after radical prostatectomy: prediction of biochemical outcomes. PLoS One 2014;9(7):e103574. DOI:10.1371/journal.pone.0103574. PMID: 25072938.; Miyake M., Tanaka N., Asakawa I. et al. Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study. Radiat Oncol 2014;9:208. DOI:10.1186/1748-717X-9208. PMID: 25331298.; Botticella A., Guarneri A., Levra N.G. et al. Biochemical and clinical outcomes after high-dose salvage radiotherapy as monotherapy for prostate cancer. Clin Oncol 2014;140(7):1111–6. DOI:10.1007/s00432-014-1673-8. PMID: 24744191.; Safdieh J.J., Schwartz D., Weiner J. et al. Long-term tolerance and outcomes for dose escalation in early salvage post-prostatectomy radiation therapy. J Radiat Oncol 2014;32(3):179–86. DOI:10.3857/roj.2014.32.3.179. PMID: 25324990.; Lohm G., Lütcke J., Jamil B. et al. Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy: long-term follow-up of a single-center survey. Strahlenther Onkol 2014;190(8):727–31. DOI:10.1007/s00066-014-0612-6. PMID: 24577132.; Briganti A., Karnes R.J., Joniau S. et al. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol 2014;66(3):479–86. DOI:10.1016/j.eururo.2013.11.045. PMID: 24345725.; Ploussard G., Staerman F., Pierrevelcin J. et al. Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatec tomy: results from a national multicen tre study. World J Urol 2014;32(5):1331–8. DOI:10.1007/s00345-013-1214-0. PMID: 24270970.; https://oncourology.abvpress.ru/oncur/article/view/902
-
10Academic Journal
Authors: N. A. Meshcheriakova, M. B. Dolgushin, A. I. Pronin, V. B. Matveev, A. A. Odzharova, D. I. Nevzorov, Н. А. Мещерякова, М. Б. Долгушин, А. И. Пронин, В. Б. Матвеев, А. А. Оджарова, Д. И. Невзоров
Source: Cancer Urology; Том 15, № 3 (2019); 70-76 ; Онкоурология; Том 15, № 3 (2019); 70-76 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2019-15-3
Subject Terms: простатический специфический антиген, 18F-fluorocholine, 18F-PSMA-1007, prostate cancer, biochemical recurrence, prostate-specific antigen, 18F-фторхолин, 18F-ПСМА-1007, рак предстательной железы, биохимический рецидив
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/967/871; Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 250 с.; Afshar-Oromieh A., Haberkorn U., Eder M. et al. [68Ga]Gallium labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging 2012;39(6):1085–6. DOI:10.1007/s00259-012-2069-0.; Morigi J.J., Stricker P.D., van Leeuwen P.J. et al. Prospective comparison of 18Ffluoromethylcholine versus 68Ga-PSMA PET/ CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 2015;56(8):1185–90. DOI:10.2967/jnumed.115.160382.; Giesel F.L., Hadaschik B., Cardinale J. et al. F18 labelled PSMA1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 2017;44:678–88.; von Eyben F.E., Kairemo K. Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun 2014;35(3):221–30. DOI:10.1097/MNM.0000000000000040.; von Eyben F.E., Picchio M., von Eyben R. et al. 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/ computed tomography for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus 2018;4(5):686–93. DOI:10.1016/j.euf.2016.11.002; Pfister D., Bolla M., Briganti A. et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol 2014;65(6):1034– 43. DOI:10.1016/j.eururo.2013.08.013.; Giesel F.L., Knorr K., Will L. et al. Detection efficacy of 18F-PSMA-1007 PET/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med 2019;60(3):362– 8. DOI:10.2967/jnumed.118.212233.; Budäus L., Leyh-Bannurah S.R., Salomon G. et al. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 2016;69(3):393–6. DOI:10.1016/j.eururo.2015.06.010.; Giesel F.L., Will L., Kesch C. et al. Biochemical recurrence of prostate cancer: initial results with 18F-PSMA-1007 PET/ CT. J Nucl Med 2018;59(4):632–5. DOI:10.2967/jnumed.117.196329.; Dietlein F., Kobe C., Neubauer S. et al. PSA-stratified performance of 18F and 68GaPSMA PET in patients with biochemical recurrence of prostate cancer. J Nucl Med 2017;58(6):947–52. DOI:10.2967/jnumed.116.185538.; Kemerink G.J., Visser M.G., Franssen R. et al. Effect of the positron range of 18F, 68Ga and 124I on PET/CT in lung equivalent materials. Eur J Nucl Med Mol Imaging 2011;38(5):940–8. DOI:10.1007/s00259-011-1732-1.; https://oncourology.abvpress.ru/oncur/article/view/967
-
11Academic Journal
Authors: M. Sh. Shikhzadaev, M. I. Shkolnik, A. A. Stanjevskiy, O. A. Bogomolov, A. L. Dolbov, М. Ш. Шихзадаев, М. И. Школьник, А. А. Станжевский, О. А. Богомолов, А. Л. Долбов
Source: Malignant tumours; Том 9, № 1 (2019); 38-41 ; Злокачественные опухоли; Том 9, № 1 (2019); 38-41 ; 2587-6813 ; 2224-5057
Subject Terms: позитронно-эмиссионная томография, prostate specific antigen, positron emission tomography, простатический специфический антиген
File Description: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/614/422; Шихзадаев М. Ш, Школьник М. И, Жаринов Г. М, Богомолов О. А, Прохоров Д. Г. Современные подходы в лечении местно распространенного рака предстательной железы // Вопросы онкологии, 2018. Том 64, № 4.; Al Monajjed R. Prostate cancer screening: controversies and suggested solutions/R. Al Monajjed, C. Arsov, P. Albers // Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. — 2018. — doi:10.1007/s00103-018-2840-x.; Sensitivity, Specificity, and Predictors of Positive 68 Ga Prostate specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta analysis/M. Perera, N. Papa, D. Christidis [et al.] // Eur Urol. — 2016. — Vol. 70, No. 6. — P. 926–937. — doi:10.1016/j.eururo.2016.06.021.; Diagnostic Efficacy of (68) Gallium PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer/T. Maurer, J. E. Gschwend, I. Rauscher [et al.] // J Urol. — 2016. — Vol. 195, No. 5. — P. 1436–1443. — doi:10.1016/j.juro.2015.12.025.; Jadvar H. Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer/H. Jadvar // Abdom Radiol (NY). — 2016. — Vol. 41, No. 5. — P. 889–898. — doi:10.1007/s00261-015-0563-0.; 68 Ga PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer/A. Herlemann, V. Wenter, A. Kretschmer [et al.] // Eur Urol. — 2016. — Vol. 70, No. 4. — P. 553–557. — doi:10.1016/j.eururo.2015.12.051.; Clinical impact of 68 Ga prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach/S. Albisinni, C. Artigas, F. Aoun [et al.] // BJU Int. — 2017. — Vol. 120, No. 2. — P. 197–203. — doi:10.1111/bju.13739.; The Role of Positron Emission Tomography With (68) Gallium (Ga) — Labeled Prostate specific Membrane Antigen (PSMA) in the Management of Patients With Organ confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatectomy/B. P. Rai, R. P. Baum, A. Patel [et al.] // Urology. — 2016. — Vol. 95. — P. 11–15. — doi:10.1016/urology.2015.12.048.; Prospective evaluation of 68 Gallium prostate specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer/P. J. van Leeuwen, L. Emmett, B. Ho [et al.] // BJU Int. — 2017. — Vol. 119, No. 2. — P. 209–215. — doi:10.1111/bju.13 540.; Nonspecific Uptake of 68 Ga Prostate Specific Membrane Antigen in Diseases other than Prostate Malignancy on Positron Emission Tomography/Computed Tomography Imaging: A Pictorial Assay and Review of Literature/D. Malik, A. Sood, B. R. Mittal [et al.] // Indian J Nucl Med. — 2018. — Vol. 33, No. 4. — P. 317–325. — doi:10.4103/ijnm.IJNM_81_18.; Assessment of 68 Ga PSMA 11 PET positivity predictive factors in prostate cancer/A. L. Gutiérrez Cardo, A. Pérez Duarte, S. F. García Argüello [et al.] // Rev Esp Med Nucl Imagen Mol. — 2018. — doi:10.1016/j.remn.2018.09.006.; Prostate imaging features that indicate benign or malignant pathology on biopsy/C. E. Lovegrove, M. Matanhelia, J. Randeva [et al.] // Transl Androl Urol. — 2018. — No. 7, Suppl. 4. — P. S420 S435. — doi:10.21037/tau.2018.07.06.; Ланг Т. А. Как описывать статистику в медицине/Т. А. Ланг, М. Сесик; пер. с англ. под ред. В. П. Леонова. — М.: Практическая медицина, 2011. — 480 с.; Jansson K. F. et al. Concordance of tumor differentiation among brothers with prostate cancer // European urology. –2012. — T.62. №. 4. — C. 656–661.; Ferlay J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 // International journal of cancer. — 2015. — T. 136. — №. 5.; https://www.malignanttumors.org/jour/article/view/614
-
12Academic Journal
Source: Наука и здравоохранение.
Subject Terms: P53, ПСА (простатический специфический антиген), қуықасты безінің қатерлі ісігі, ПТА (простатаға тән антиген), PSA (prostate specific antigen), иммуногистохимиялық маркерлер, Ki-67, иммуногистохимические маркеры, prostate cancer, immunohistochemical markers, рак предстательной железы, 3. Good health
-
13Academic Journal
Authors: L. M. Rapoport, E. A. Bezrukov, R. B. Sukhanov, G. E. Krupinov, D. G. Tsarichenko, G. A. Martirosyan, S. K. Avakyan, Л. М. Рапопорт, Е. А. Безруков, Р. Б. Суханов, Г. Е. Крупинов, Д. Г. Цариченко, Г. А. Мартиросян, С. К. Авакян
Source: Andrology and Genital Surgery; Том 19, № 1 (2018); 68-76 ; Андрология и генитальная хирургия; Том 19, № 1 (2018); 68-76 ; 2412-8902 ; 2070-9781 ; 10.17650/2070-9781-2018-19-1
Subject Terms: простатический специфический антиген, diagnosis, biomarkers, biopsy, prostate specific antigen, диагностика, биомаркеры, биопсия
File Description: application/pdf
Relation: https://agx.abvpress.ru/jour/article/view/281/262; Алексеев Б.Я., Каприн А.Д., Матвеев В.Б., Нюшко К.М. Клинические рекомендации по диагностике и лечению рака предстательной железы. М., 2014. 44 с. Доступно по: http://oncology-association.ru/docs/recomend/may2015/39vz-rek.pdf; American Cancer Society. Cancer Facts & Figures. 2017. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf.; Vickers A., Cronin A., Roobol M. et al. Reducing unnecessary biopsy during prostate cancer screening using a fourkallikrein panel: an independent replication. J Clin Oncol 2010;28(15):2493–8. DOI:10.1200/JCO.2009.24.1968. PMID: 20421547.; Куплевацкий В.И., Черкашин М.А., Рощин Д.А. и др. Биопсия предстательной железы под контролем магнитно-резонансной томографии. Вестник рентгенологии и радиологии 2016;97(1):48–55. DOI:10.20862/0042-4676-2016-97-1-48-55.; Архипова О.Е., Черногубова Е.А., Куролап С.А., Епринцев С.А. Эпидемиология рака предстательной железы в Воронежской области: пространственно-временная статистика. Вестник урологии 2016;(4):45–55. DOI:10.1234/XXXX-XXXX-2016-4-45-55.; Gathirua-Mwangi W.G., Zhang J. Dietary factors and risk for advanced prostate cancer. Eur J Cancer Prev 2014;23(2):96–109. DOI:10.1097/CEJ.0b013e3283647394. PMID: 23872953.; Schröder F.H., Hugosson J., Roobol M.J. et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384(9959):2027–35. DOI:10.1016/S0140-6736(14)60525-0. PMID: 25108889.; Thompson I.M., Pauler D.K., Goodman P.J. et al. Prevalence of prostate cancer among men with a prostatespecific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350(22): 2239–46. DOI:10.1056/NEJMoa031918. PMID: 15163773.; Kretschmer A., Tilki D. Biomarkers in prostate cancer – current clinical utility and future perspectives. Crit Rev Oncol Hematol 2017;120:180–93. DOI:10.1016/j.critrevonc.2017.11.007. PMID: 29198331.; Stamey T.A., Yang N., Hay A.R. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317(15):909–16. DOI:10.1056/NEJM198710083171501. PMID: 2442609.; Semjonow A., Brandt B., Oberpenning F. et al. Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate Suppl 1996;7:3–16. PMID: 8950358.; Parekh D.J., Punnen S., Sjoberg D.D. et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol 2015;68(3):464–70. DOI:10.1016/j. eururo.2014.10.021. PMID: 25454615.; Salami S.S., Schmidt F., Laxman B. et al. Combining urinary detection of TMPRSS2: ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol 2013;31(5):566–71. DOI:10.1016/j.urolonc.2011.04.001. PMID: 21600800.; Пушкарь Д.Ю., Говоров А.В., Сидоренков А.В. и др. Ранняя диагностика рака предстательной железы: методические рекомендации № 19. М.: АБВ-пресс, 2015. 54 с.; Catalona W.J., Smith D.S., Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA, 1997. 277(18): p. 1452–5.; Catalona W.J., Partin A.W., Slawin K.M. et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279(19):1542–7. PMID: 9605898.; Catalona W.J., Smith D.S., Wolfert R.L. et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274(15):1214–20. PMID: 7563511.; Filella X., Gimenez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2013;51(4):729–39. DOI:10.1515/cclm-2012-0410. PMID: 23154423.; Ito K., Miyakubo M., Sekine Y. et al. Diagnostic significance of [-2] pro-PSA and prostate dimension-adjusted PSArelated indices in men with total PSA in the 2.0–10.0 ng/mL range. World J Urol 2013;31(2):305–11. DOI:10.1007/s00345-012-0927-9. PMID: 22903772.; Tosoian J.J., Druskin S.C., Andreas D. et al. Prostate Health Index density improves detection of clinically significant prostate cancer. BJU Int 2017;120(6):793–8. DOI:10.1111/bju.13762. PMID: 28058757.; Mottet N., Bellmunt J., Bolla M. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2017;71(4):618–29. DOI:10.1016/j.eururo.2016.08.003. PMID: 27568654.; NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx.; Leyten G.H., Hessels D., Smit F.P. et al. Identification of a candidate gene panel for the early diagnosis of prostate cancer. Clin Cancer Res 2015;21(13):3061–70. DOI:10.1158/107800432.CCR-140-3334. PMID: 25788493.; Van Neste L., Hendriks R.J., Dijkstra S. et al. Detection of high-grade prostate cancer using a Urinary Molecular Biomarker-Based Risk Score. Eur Urol 2016;70(5):740–8. DOI:10.1016/j.eururo.2016.04.012. PMID: 27108162.; Chan T.A., Glockner S., Yi J.M. et al. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med 2008;5(5):e114. DOI:10.1371/journal.pmed.0050114. PMID: 18507500.; Van Neste L., Herman J.G., Otto G. et al. The epigenetic promise for prostate cancer diagnosis. Prostate 2012;72(11):1248–61. DOI:10.1002/pros.22459. PMID: 22161815.; Henrique R., Jerόnimo C., Teixeira M.R. et al. Epigenetic heterogeneity of highgrade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol Cancer Res 2006;4(1):1–8. DOI:10.1158/1541-7786.MCR-05-0113. PMID: 16446401.; Henrique R., Jerόnimo C. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol 2004;46(5):660–9. DOI:10.1016/j.eururo.2004.06.014. PMID: 15474280.; Woodson K., O’Reilly K.J., Hanson J.C. et al. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J Urol 2008;179(2):508–11. DOI:10.1016/j.juro.2007.09.073. PMID: 18076912.; Gurioli G., Martignano F., Salvi S. et al. GSTP1 methylation in cancer: a liquid biopsy biomarker? Clin Chem Lab Med 2018 Jan 6. DOI:10.1515/cclm-2017-0703. PMID: 29305565.; Fradet Y., Saad F., Aprikian A. et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004;64(2):311–5. DOI:10.1016/j.urology.2004.03.052. PMID: 15302485.; Hansen J., Auprich M., Ahyai S.A. et al. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol 2013;63(2):201–9. DOI:10.1016/j.eururo.2012.07.030. PMID: 22854248.; De la Taille A., Irani J., Graefen M. et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol 2011;185(6):2119–25. DOI:10.1016/j.juro.2011.01.075. PMID: 21496856.; Tomlins S.A., Day J.R., Lonigro R.J. et al. Urine TMPRSS2: ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol 2016;70(1):45–53. DOI:10.1016/j.eururo.2015.04.039. PMID: 25985884.; Nilsson J., Skog J., Nordstrand A. et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer 2009;100(10):1603–7. PMID: 19401683.; Donovan M.J., Noerholm M., Bentink S. et al. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. Prostate Cancer Prostatic Dis 2015;18(4):370–5. DOI:10.1038/pcan.2015.40. PMID: 26345389.; McKiernan J., Donovan M.J., O»Neill V. et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol 2016;2(7):882–9. DOI:10.1001/jamaoncol.2016.0097. PMID: 27032035.; https://agx.abvpress.ru/jour/article/view/281
-
14Academic Journal
Source: Cancer Urology; Том 13, № 1 (2017); 91-100 ; Онкоурология; Том 13, № 1 (2017); 91-100 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2017-13-1
Subject Terms: трансректальное ультразвуковое исследование, atypical small acinar proliferation, targeted biopsy of the suspicious area, prostate-specific antigen, multiparametric magnetic resonance imaging, transrectal ultrasonography, атипическая мелкоацинарная пролиферация, целевая биопсия подозрительной зоны предстательной железы, простатический специфический антиген, мультипараметрическая магнитно-резонансная томография
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/631/627; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/631/370; Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.; Океанов А.Е., Моисеев П.И., Левин Л.Ф. Статистика онкологических заболеваний в Республике Беларусь (2005–2014). Под ред. О.Г. Суконко. Минск: РНПЦ ОМР им. Н.Н. Александрова, 2015. [Okeanov A.E., Moiseev P.I., Levin L.F. Statistics of oncologic diseases in the Republic of Belarus (2005–2014). Ed. by O.G. Sukonko. Minsk: RNPTS OMR im. N.N. Alexandrova, 2015. (In Russ.)].; Суконко О.Г., Красный А.С., Океанов А.Е. и др. Рак предстательной железы в Республике Беларусь: вчера, сегодня, завтра. Здравоохранение 2013;(11):34–42. [Sukonko O.G., Krasnyy A.S., Okeanov A.E. et al. Prostate cancer in the Republic of Belarus: yesterday, today and tomorrow. Zdravookhranenie = Healthcare 2013;(11):34–42. (In Russ.)].; Leone A., Gershman B., Rotker K. et al. Atypical small acinar proliferation (ASAP): is a repeat biopsy necessary ASAP? A multiinstitutional review. Prostate Cancer Prostatic Dis 2016;19(1):68–71. DOI:10.1038/pcan.2015.52. PMID: 26857145.; Cheville J.C., Reznicek M.J., Bostwick D.G. The focus of “atypical glands, suspicious for malignancy” in prostatic needle biopsy specimens: incidence, histologic features, and clinical follow-up of cases diagnosed in a community practice. Am J Clin Pathol 1997;108(6):633–40. PMID: 9384444.; Wolters T., van der Kwast T.H., Vissers C.J. et al. False-negative prostate needle biopsies: frequency, histopathologic features, and followup. Am J Surg Pathol 2010;34(1):35–43. DOI:10.1097/PAS.0b013e3181c3ece9. PMID: 19935058.; Maccagnano C., Gallina A., Roscigno M. et al. Prostate saturation biopsy following a first negative biopsy: state of the art. Urol Int 2012;89(2):126–35. DOI:10.1159/000339521. PMID: 22814003.; Садченко А.В., Говоров А.В., Пушкарь Д.Ю., Васильев А.О. Сатурационная биопсия предстательной железы (обзор литературы). Онкоурология 2013;(3):70–5. [Sadchenko A.V., Govorov A.V., Pushkar’ D.Yu., Vasil’ev A.O. Saturation biopsy of the prostate (review). Onkourologiya = Oncourology 2013;(3):70–5. (In Russ.)]. DOI:10.17650/1726-9776-2013-9-3-70-75.; Юсупова И.Р., Казимирова А.А. Сравнительная оценка экспрессии маркера D2-40 эндотелием лимфатических сосудов при атипичной мелкоацинарной пролиферации и аденокарциноме предстательной железы. Бюллетень медицинских интернет-конференций 2015;5(5):689–91. [Yusupova I.R., Kazimirova A.A. Comparative evaluation of the expression of marker D2-40 by endothelial of lymphatic vessels at atypical small acinar proliferation and adenocarcinoma of the prostate. Byulleten’ meditsinskikh internet-konferentsiy = Bulletin of Medical Internet Conferences 2015;5(5):689–91. (In Russ.)].; Геворкян А.Р., Авакян А.Ю., Павлюк М.Д. Анализ результатов биопсий и ребиопсий предстательной железы в окружном урологическом отделении Западного административного округа г. Москвы за трехлетний период. Эффективная фармакотерапия. Урология и нефрология 2013;(1):11–3. [Gevorkyan A.R., Avakyan A.Yu., Pavlyuk M.D. Analysis of the results of biopsy and rebiopsy of prostate in district urology department of the Western Administrative District of the city of Moscow for a three-year period. Effektivnaya farmakoterapiya. Urologiya i nefrologiya = Effective Pharmacotherapy. Urology and Nephrology 2013;(1):11–3. (In Russ.)].; Казимирова А.А., Юсупова И.Р. Атипичная мелкоацинарная пролиферация и аденокарцинома предстательной железы: структурно-биохимические сопоставления. Уральский медицинский журнал 2014;(8):91–6. [Kazimirova A.A., Yusupova I.R. Atypical small acinar proliferation and adenocarcinoma of the prostate: structural and biochemical mapping. Ural’skiy meditsinskiy zhurnal = Ural Medical Journal 2014;(8):91–6. (In Russ.)].; Курджиев М.А., Говоров А.В., Ковылина М.В., Пушкарь Д.Ю. Повторная трансректальная биопсия предстательной железы у пациентов с атипической мелкоацинарной пролиферацией: оптимальные сроки и особенности проведения. Онкоурология 2009;(4):50–3. [Kurdzhiev M.A., Govorov A.V., Kovylina M.V., Pushkar’ D.Yu. Repeated transrectal prostate biopsy in patients with atypical small acina. Onkourologiya = Oncourology 2009;(4):50–3. (In Russ.)]. DOI:10.17650/1726-9776-2009-5-4-50-53.; Kawachi M.H., Bahnson R.R., Barry M. et al. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw 2010;8(2):240–62. PMID: 20141680.; Мищенко А.В. Комплексное магнитнорезонансное исследование в диагностике заболеваний внутренних половых органов у мужчин. Автореф. дис. … д-ра мед. наук. СПб, 2010. [Mischenko A.V. Complex magnetic resonance imaging in the diagnosis of the disease of internal genital organs in men. Author’s abstract of thesis … of doctor of medical sciences. Saint Petersburg, 2010. (In Russ.)].; Рубцова Н.А., Алексеев Б.Я., Мамонтова И.С. и др. Возможности МРТ в диагностике локализованной формы рака предстательной железы. Медицинская визуализация 2014;(1):124–6. [Rubtsova N.A., Alekseev B.Ya., Mamontova I.S. et al. Role of MRI in the diagnosis of localized prostate cancer. Meditsinskaya vizualizatsiya = Medical Imaging 2014;(1):124–6. (In Russ.)].; Fütterer J.J., Verma S., Hambrock T. et al. High-risk prostate cancer: value of multimodality 3T MRI-guided biopsies after previous negative biopsies. Abdom Imaging 2012;37(5):892–6. DOI:10.1007/s00261-011-9818-6. PMID: 22038330.; Bjurlin M.A., Meng X., Le Nobin J. et al. Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. J Urol 2014;192(3):648–58. DOI:10.1016/j.juro.2014.03.117. PMID: 24769030.; Mearini L., Costantini E., Bellezza G. et al. Is there any clinical parameter able to predict prostate cancer after initial diagnosis of atypical small acinar proliferation? Urol Int 2008;81(1):29–35. DOI:10.1159/000137637. PMID: 18645268.; Leone L., Lacetera V., Montironi R. et al. Biopsy follow-up in patients with isolated atypical small acinar proliferation (ASAP) in prostate biopsy. Arch Ital Urol Androl 2014;86(4):332–5. DOI:10.4081/aiua.2014.4.332. PMID: 25641465.; Карман А.В., Леусик Е.А., Дударев В.С. Сатурационная трансректальная биопсия в диагностике рака предстательной железы у мужчин с отрицательным результатом первичной мультифокальной биопсии. Онкологический журнал 2014;8(31):31–40. [Karman A.V., Leusik E.A., Dudarev V.S. Saturation transrectal biopsy in prostate cancer diagnosing in men with negative primary multifocal biopsy. Onkologicheskiy zhurnal = Oncological Journal 2014;8(31):31–40. (In Russ.)].; Boesen L., Noergaard N., Chabanova E. et al. Early experience with multiparametric magnetic resonance imaging-targeted biopsies under visual transrectal ultrasound guidance in patients suspicious for prostate cancer undergoing repeated biopsy. Scand J Urol 2015;49(1):25–34. DOI:10.3109/21681805.2014.925497. PMID: 24922550.; Junker D., Schäfer G., Heidegger I. et al. Multiparametric magnetic resonance imaging/ transrectal ultrasound fusion targeted biopsy of the prostate: preliminary results of a prospective single-centre study. Urol Int 2015;94(3):313–8. DOI:10.1159/000365489. PMID: 25591786.; Prostate Imaging Reporting and Data System (PI-RADS). Available at: http://www.acr.org/Quality-Safety/Resources/PIRADS/.; Карман А.В., Леусик Е.А. Диагностические возможности системы PI-RADS у пациентов, перенесших первичную мультифокальную биопсию предстательной железы с негативными ее результатами. Онкологический журнал 2014;8(2):20–7. [Karman A.V., Leusik E.A. Diagnostic potential of PI-RADS for patients with negative results of initial multifocal biopsy. Onkologicheskiy zhurnal = Oncological Journal 2014;8(2):20–7. (In Russ.)].; Franiel T., Stephan C., Erbersdobler A. et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding – multiparametric MR imaging for detection and biopsy planning. Radiology 2011;259(1):162–72. DOI:10.1148/radiol.10101251. PMID: 21233291.; https://oncourology.abvpress.ru/oncur/article/view/631
-
15Academic Journal
Authors: V. B. Matveev, A. S. Markova, В. Б. Матвеев, А. С. Маркова
Source: Cancer Urology; Том 13, № 2 (2017); 79-86 ; Онкоурология; Том 13, № 2 (2017); 79-86 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2017-13-2
Subject Terms: агонист лютеинизирующего гормона рилизинг-гормона, leuproreline acetate, Eligard, non-interventional study, testosterone, prostatic specific antigen, quality of life, luteinizing hormone releasing hormone agonist, лейпрорелина ацетат, Элигард, неинтервенционное исследование, тестостерон, простатический специфический антиген, качество жизни
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/689/662; Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 250 с. [Malignant tumors in Russia in 2015 (morbidity and fatality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2017. 250 p. (In Russ.)].; Состояние онкологической помощи населению России в 2016 году. Под ред. Каприна А.Д., Старинского В.В., Петровой Г.В. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 236 с. [State of oncological care in Russia in 2015. Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2016. 236 p. (In Russ.)].; Guidelines on Prostate Cancer. European Association of Urology (EAU). 2017. 146 p.; Hedlund P.O., Damber J.E., Hagerman I. et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2008;42(3):220–9. DOI:10.1080/00365590801943274. PMID: 18432528.; Seidenfeld J., Samson D.J., Hasselblad V. et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132(7):566–77. PMID: 10744594.; Klotz L., Boccon-Gibod L., Shore N.D. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102(11):1531–8. DOI:10.1111/j.1464-410X.2008.08183.x. PMID: 19035858.; Guidelines on Prostate Cancer. European Association of Urology (EAU). 2015. 137 p.; Perez-Marreno R., Chu F.M., Gleason D. et al. A six-month, open-label study assessing a new formulation of leuprolide 7,5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 2002;24(11):1902–14. PMID: 12501882.; Perez-Marreno R., Tyler R.C. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(2):447–57. DOI:10.1517/14656566.5.2.447. PMID: 14996640.; Chu F.M., Jayson M., Dineen M.K. et al. A clinical study of 22.5 mg. La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002;168(3):1199–203. DOI:10.1097/01.ju.0000023895.95963.1b. PMID: 12187267.; Crawford E.D., Sartor O., Chu F. et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006;175(2):533–6. DOI:10.1016/S0022-5347(05)00161-8. PMID: 16406989.; Kunath F., Grobe H.R., Rücker G. et al. Non-steroidal antiandrogen monotherapy compared with luteinising hormonereleasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database Syst Rev 2014;6:CD009266. DOI:10.1002/14651858.CD009266.pub2. PMID: 24979481.; Montorsi F., Tomlinson P. Which luteinising hormone-releasing hormone agonist injection schedule do men with prostate cancer prefer? Results of a European patient survey. Eur Urol 2015;67(1):177–9. DOI:10.1016/j.eururo.2014.08.055. PMID: 25220374.; Tunn U.W. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urology 2011;11:15. DOI:10.1186/1471-2490-11-15. PMID: 21801354. Available at: http://www.biomedcentral. com/1471-2490/11/15.; Braeckman J., Michielsen D. Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard®/Depo-Eligard®) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study. Arch Med Sci 2014;10(3): 477–83. DOI:10.5114/aoms.2014.43743. PMID: 25097577.; https://oncourology.abvpress.ru/oncur/article/view/689
-
16Academic Journal
Source: Креативная хирургия и онкология, Vol 0, Iss 3, Pp 28-34 (2017)
Subject Terms: простатический специфический антиген, показатель глисона, рак предстательной железы, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Relation: https://www.surgonco.ru/jour/article/view/169; https://doaj.org/toc/2307-0501; https://doaj.org/toc/2076-3093; https://doaj.org/article/94e099164515414f9c123f5eb4dfa11c
-
17Academic Journal
Authors: Мур, M.A.
Source: Наука и здравоохранение.
Subject Terms: қуықастыбезі қатерлі ісігі, ПСА (простатический специфический антиген), стадия рака, Semey region, скрининг рака, Семей аймағы, ұатерлі ісік скринингі, prostate cancer, рак предстательной железы, 3. Good health, PSA, cancer stage, cancer screening, ПСА, қатерлі ісік кезеңі, Семейский регион
-
18Academic Journal
Authors: N. S. Sergeeva, T. E. Skachkova, B. Ya. Alekseev, E. F. Yurkov, S. A. Pirogov, V. G. Gitis, N. V. Marshutina, A. D. Kaprin, Н. С. Сергеева, Т. Е. Скачкова, Б. Я. Алексеев, Е. Ф. Юрков, С. А. Пирогов, В. Г. Гитис, Н. В. Маршутина, А. Д. Каприн
Source: Cancer Urology; Том 12, № 4 (2016); 94-103 ; Онкоурология; Том 12, № 4 (2016); 94-103 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2016-12-4
Subject Terms: индекс здоровья предстательной железы, prostate-specific antigen, totPSA, freePSA, [-2]proPSA, prostate health index, простатический специфический антиген, общПСА, свПСА, [-2]проПСА
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/587/610; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/587/256; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/587/257; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/587/258; Catalona W.J., Partin A.W., Sanda M.G. et al. A multi-center study of [-2]Pro-prostate-specific antigen (PSA) in combination with PSA and free PSA for prostate cancer detection in the 2.0 to 10.0 ng/mL PSA Range. J Urol 2011;185(5): 1650–5.; Петрова Г.В., Каприн А.Д., Старинский В.В., Грецова О.П. Заболеваемость злокачественными новообразованиями населения России. Онкология. Журнал им. П.А. Герцена 2014;(5):5–10. [Petrova G.V., Kaprin A.D., Starinskiy V.V., Gretsova O.P. Morbidity of malignant neoplasms in Russian population. Onkologiya. Zhurnal im. P.A. Hertsena = Oncology P.A. Hertzen Journal 2014;(5): 5–10. (In Russ.)].; Sardana G., Dowell B., Diamandis E.P. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 2008;52(12):1951–60. DOI:10.1373/clinchem.2008.110668. PMID: 18927246.; Postma R., Schröder F.H. Screening for prostate cancer. Eur J Cancer 2005;41(6):825–33. DOI:10.1016/j.ejca.2004.12.029. PMID: 15808952.; Schröder F.H., Hugosson J., Roobol M.J. et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366(11): 981–90. DOI:10.1056/NEJMoa1113135. PMID: 22417251.; Собин Л.Х., Господарович М.К., Виттекинд К. TNM. Классификация злокачественных опухолей. М.: Логосфера, 2011. [Sobin L.Kh., Gospodarovich M.K., Vittekind K. TNM. Classification of malignant tumors. Moscow: Logosfera, 2011. (In Russ.)].; Cantiello F., Russo G.I., Cicione A. et al. PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance. World J Urol 2015 [ahead of print].; Kryvenko O.N., Carter H.B., Trock B.J., Epstein J.I. Biopsy criteria for determining appropriateness for active surveillance in the modern era. Urology 2014;83(4):869–74. DOI:10.1016/j.urology.2013.12.054. PMID: 24680457.; Han J.S., Toll A.D., Amin A. et al. Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy. Urology 2012;80(4): 883–8. DOI:10.1016/j.urology.2012.05.045. PMID: 22921697.; https://oncourology.abvpress.ru/oncur/article/view/587
-
19Academic Journal
Authors: V. A. Solodkiy, A. Yu. Pavlov, A. D. Tsybul’skiy, В. А. Солодкий, А. Ю. Павлов, А. Д. Цыбульский
Source: Cancer Urology; Том 12, № 4 (2016); 81-86 ; Онкоурология; Том 12, № 4 (2016); 81-86 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2016-12-4
Subject Terms: простатический специфический антиген, prostate cancer recurrence, salvage brachytherapy, life-saving brachytherapy, high dose brachytherapy, high dose rate brachytherapy, interstitial radiation therapy, prostate-specific antigen, рецидив рака предстательной железы, сальважная брахитерапия, спасительная брахитерапия, высокодозная брахитерапия, высокомощностная брахитерапия, внутритканевая лучевая терапия
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/599/608; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/599/321; Liu J., Kaidu M., Sasamoto R. et al. Two-fraction high-dose-rate brachytherapy within a single day combined with external beam radiotherapy forprostate cancer: single institution experience and outcomes. J Radiat Res 2016;57(3):280–7. DOI:10.1093/jrr/rrw003. PMID: 26983988.; Gabriele D., Jereczek-Fossa B.A., Krengli M. et al. Beyond D’Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier. Radiat Oncol 2016;11(1):23. DOI:10.1186/s13014-016-0599-5. PMID: 26911291.; Olarte A., Cambeiro M., Moreno-Jiménez M. et al. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes. Brachytherapy 2016;15(2):127–35. DOI:10.1016/j.brachy.2015.12.008. PMID: 26832677.; Garibaldi E., Gabriele D., Maggio A. et al. External beam radiotherapy with dose escalation in 1080 prostate cancer patients: definitive outcome and dose impact. Panminerva Med 2016;58(2):121–9. PMID: 26785374.; Bolla M., Van Tienhoven G., Warde P., et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study. Lancet Oncol 2010;11:1066–73.; Jo Y., Fujii T., Hara R. et al. Salvage highdose-rate brachytherapy for local prostate cancer recurrence after radiotherapy – preliminary results. BJU Int 2012;109(6):835–9. DOI:10.1111/j.1464-410X.2011.10519.x. PMID: 21933327.; Matei D.V., Ferro M., Jereczek-Fossa B.A. et al. Salvage radical prostatectomy after external beam radiation therapy: a systematic review of current approaches. Urol Int 2015;94(4):373–82. DOI:10.1159/000371893. PMID: 25765848.; Berlin A., Fernandez M.I. Avances en el tratamiento de cancer de prostata resistente a la castracion: enfasis en nuevas terapias hormonales. Rev Méd Chile 2015;(2):143–9.; Grado G.L., Collins J.M., Kriegshauser J.S. et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53(1):2–10. PMID: 9886580.; Aaronson D.S., Yamasaki I., Gottschalk A. et al. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int 2009;104(5):600–4. DOI:10.1111/j.1464-410X.2009.08445.x. PMID: 19245439.; Lee B., Shinohara K., Weinberg V. et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California, San Francisco experience. Int J Radiat Oncol Biol Phys 2007;67(4):1106–12. DOI:10.1016/j.ijrobp.2006.10.012. PMID: 17197119.; Nguyen P.L., Chen R.C., Clark J.A. et al. Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: a prospective Phase II study. Brachytherapy 2009;8(4):345–52. DOI:10.1016/j.brachy.2009.01.004. PMID: 19428311.; Beyer D.C. Brachytherapy for recurrent prostate cancer after radiation therapy. Semin Radiat Oncol 2003;13(2):158–65. DOI:10.1053/srao.2003.50015. PMID: 12728445.; https://oncourology.abvpress.ru/oncur/article/view/599
-
20Academic Journal
Authors: V. B. Matveev, A. S. Markova, В. Б. Матвеев, А. С. Маркова
Source: Cancer Urology; Том 12, № 2 (2016); 84-91 ; Онкоурология; Том 12, № 2 (2016); 84-91 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2016-12-2
Subject Terms: Элигард, hormone therapy, testosterone, prostate specific antigen, luteinising hormone-releasing hormone agonists, leuprorelin acetate, Eligard, гормональная терапия, тестостерон, простатический специфический антиген, агонисты лютеинизирующего гормона рилизинг-гормона, лейпрорелина ацетат
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/580/552; https://oncourology.abvpress.ru/oncur/article/view/580/567; Состояние онкологической помощи в 2014 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена, 2015. 236 с. [Cancer care status in 2014. Eds. by: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Мoscow: P.A. Herzen МSROI, 2015. 236 p. (In Russ.)].; Guidelines on Prostate Cancer. European Association of Urology (EAU). 2015. 137 p.; Eisenberger M.A., Blumenstein B.A., Crawford E.D. et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339(15):1036–42.; Akaza H., Hinotsu S., Usami M. et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, doubleblind, randomized study for survival. Cancer 2009;115(15):3437–45.; Schmitt B., Bennett C., Seidenfeld J. et al. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2000;(2):CD001526.; Tsushima T., Nasu Y., Saika T. et al. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. Urol Int 2001;66(3):135–9.; Klotz L., Boccon-Gibod L., Shore N.D. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, openlabel, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102(11): 1531–8.; Seidenfeld J., Samson D.J., Hasselblad V. et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132(7):566–77.; Hedlund P.O., Damber J.E., Hagerman I. et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2008;42(3):220–9.; Crawford E.D., Moul J.W., Sartor O., Shore N.D. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. Expert Opin. Drug Metab. Toxicol 2015;11(9):1465–74.; Oefelein M.G., Feng A., Scolieri M.J. et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56(6): 1021–4.; Fizazi K., Scher H.I., Molina A. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13(10): 983–92.; Ryan C.J., Smith M.R., Fizazi K. et al. Final overall survival (OS) analysis of COUAA- 302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients without prior chemotherapy. Ann Oncol 2014;25:iv255–79.; Klotz L., O’Callaghan C., Ding K. et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol 2015;33(10):1151–6.; Hussain M., Tangen C.M., Higano C. et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic rostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24(24):3984–90.; Crawford E.D., Sartor O., Chu F. et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006;175(2): 533–6.; Tunn U.W. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urol 2011;11:15.; Braeckman J., Michielsen D. Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard®/Depo- Eligard®) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study. Arch Med Sci 2014;10(3);477–83.; https://oncourology.abvpress.ru/oncur/article/view/580